Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer

Anixa Biosciences (ANIX) announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the company’s follicle-stimulating hormone receptor-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer. Several trial participants have lived significantly beyond their median expected survival of three to four months, based on disease stage and prior therapy history. One patient survived 28 months following treatment, three patients have survived greater than one year following treatment, at 18, 17 and 17 months, respectively, and four additional patients have survived 11, 11, 8 and 7 months, respectively. Three of the patients who reached 18, 17 and 11 months, respectively, remain alive, and one additional patient who was treated more recently is also currently alive. No dose-limiting toxicities have been encountered in the first three dose cohorts. All significant adverse events observed to date have been unrelated to lira-cel administration. The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. The trial is designed to evaluate the safety and tolerability of lira-cel, determine the maximum tolerated dose, and assess preliminary evidence of clinical activity.